Future in vivo studies in an animal model of obesity are required to delineate the potential benefit of altering the CCR4/CCL17/CCL22 signalling in vivo and assess the therapeutic window of CCR4 inhibition. The gene discussed is CCR4; the disease is obesity due to melanocortin 4 receptor deficiency.